Latest & greatest articles for amoxicillin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on amoxicillin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on amoxicillin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for amoxicillin

81. A clinical and economic comparison of roxithromycin 150 mg twice daily vs amoxicillin 500mg/calvulanic acid 125mg three times daily for the treatment of lower respiratory tract infections in general practice

A clinical and economic comparison of roxithromycin 150 mg twice daily vs amoxicillin 500mg/calvulanic acid 125mg three times daily for the treatment of lower respiratory tract infections in general practice A clinical and economic comparison of roxithromycin 150 mg twice daily vs amoxicillin 500mg/calvulanic acid 125mg three times daily for the treatment of lower respiratory tract infections in general practice A clinical and economic comparison of roxithromycin 150 mg twice daily vs (...) amoxicillin 500mg/calvulanic acid 125mg three times daily for the treatment of lower respiratory tract infections in general practice Karalus N C, Garrett J E, Lang S D, Scott W G, Leng R A, Kostalas G N, Cursons R T, Cooper B C, Scott H M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability

1994 NHS Economic Evaluation Database.

82. Treatment of streptococcal pharyngitis with amoxycillin once a day. Full Text available with Trip Pro

Treatment of streptococcal pharyngitis with amoxycillin once a day. To evaluate treatment of group A beta haemolytic streptococcal pharyngitis with amoxycillin once daily compared with phenoxymethylpenicillin three or four times a day.Randomised controlled study of consecutive patients presenting with symptoms suggestive of group A beta haemolytic streptococcal pharyngitis in whom culture of a throat swab yielded positive results.Five family medicine practices.157 patients aged over 3 years who (...) required treatment with antibiotics.Clinical response, bacteriological response, days at work and school lost, and compliance.During the period of the study 393 patients presented with symptoms suggesting streptococcal pharyngitis; 157 of them had throat swabs that yielded positive results on culture. Eighty two were treated with phenoxymethylpenicillin and 75 with amoxycillin. No difference was observed in the clinical response, days at work and school lost (139 days for 64 patients taking

1993 BMJ Controlled trial quality: uncertain

83. Effect of ranitidine and amoxicillin plus metronidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer. (Abstract)

Effect of ranitidine and amoxicillin plus metronidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer. Persistent infection with Helicobacter pylori is associated with the recurrence of duodenal ulcer. Whether the efficacy of bismuth therapy in reducing the rate of recurrence of duodenal ulcer is due to its antimicrobial effects on H. pylori or to a direct protective action on the mucosa is still a matter of debate.To study the effect of the eradication of H (...) . pylori on the recurrence of duodenal ulcer, we treated 104 patients with H. pylori infection and recurrent duodenal ulcer with either amoxicillin (750 mg three times daily) plus metronidazole (500 mg three times daily) or identical-appearing placebos, given orally for 12 days. All patients also received ranitidine (300 mg each night) for 6 or 10 weeks. Endoscopy was performed before treatment and periodically during follow-up for up to 12 months after healing.Among the 52 patients given antibiotics

1993 NEJM Controlled trial quality: uncertain

84. Amoxycillin plus probenecid versus doxycycline for treatment of erythema migrans borreliosis. (Abstract)

Amoxycillin plus probenecid versus doxycycline for treatment of erythema migrans borreliosis. 72 adults with erythema migrans (early Lyme borreliosis) were enrolled in a randomised prospective trial comparing amoxycillin 500 mg plus probenecid 500 mg three times a day with doxycycline 100 mg twice a day for 21 days. These antibiotic regimens were chosen because of the known in-vitro sensitivity of Borrelia burgdorferi, the antibiotic tissue penetration, the pharmacokinetics of the drugs (...) , and because the organism can disseminate early in the course of infection. 72 patients were evaluable (35 in the doxycycline group and 37 in the amoxycillin/probenecid group). The two regimens were equally effective for treatment of erythema migrans. Mild fatigue or arthralgia were the only post-treatment complaints, which resolved within 6 months. None of the patients needed further antibiotic treatment for Lyme borreliosis.

1990 Lancet Controlled trial quality: uncertain

85. Randomised study of myringotomy, amoxycillin/clavulanate, or both for acute otitis media in infants. (Abstract)

Randomised study of myringotomy, amoxycillin/clavulanate, or both for acute otitis media in infants. In a prospective study, 105 infants aged 3-12 months with acute otitis media were randomly assigned to one of three treatment groups: amoxycillin/clavulanate ('Augmentin') alone (36 patients), myringotomy plus placebo (35 patients), or augmentin plus myringotomy (34 patients). The last two groups were double-blinded. Bacterial pathogens, mainly Haemophilus influenzae (of which 20% were beta

1989 Lancet Controlled trial quality: uncertain

86. Efficacy of amoxicillin with and without decongestant-antihistamine for otitis media with effusion in children. Results of a double-blind, randomized trial. Full Text available with Trip Pro

Efficacy of amoxicillin with and without decongestant-antihistamine for otitis media with effusion in children. Results of a double-blind, randomized trial. In a randomized, double-blind, placebo-controlled trial involving 518 infants and children who had otitis media with effusion ("secretory" otitis media), we evaluated the efficacy of a two-week course of amoxicillin (40 mg per kilogram of body weight per day) with and without a four-week course of an oral decongestant-antihistamine (...) combination. Among the 474 subjects who were evaluated at the four-week end point, the rate of resolution of middle-ear effusion was twice as high in those treated with amoxicillin, either with or without the decongestant-antihistamine, as in those who received placebo (P less than 0.001), but 69.8 percent of the amoxicillin-treated subjects still had effusion. Among both the amoxicillin-treated subjects and the placebo-treated subjects, resolution was more likely in those with initially unilateral

1987 NEJM Controlled trial quality: predicted high

87. Single-dose therapy for cystitis in women. A comparison of trimethoprim-sulfamethoxazole, amoxicillin, and cyclacillin. (Abstract)

Single-dose therapy for cystitis in women. A comparison of trimethoprim-sulfamethoxazole, amoxicillin, and cyclacillin. We evaluated single-dose regimens of trimethoprim-sulfamethoxazole, amoxicillin, and cyclacillin as treatment for acute cystitis in 38 women. The trial was prematurely stopped because of frequent treatment failures. At two days after treatment, all 13 patients given trimethoprim-sulfamethoxazole were cured, while four (31%) of 13 given amoxicillin and four (33%) of 12 given (...) cyclacillin had persistent bacteriuria. At two weeks, 11 (85%) of 13 patients given trimethoprim-sulfamethoxazole, six (50%) of 12 given amoxicillin, and three (30%) of ten given cyclacillin were cured. One patient with positive results of antibody-coated bacteria testing who was treated with cyclacillin had signs and symptoms of acute pyelonephritis three days after treatment, and two patients treated with amoxicillin and one treated with trimethoprim-sulfamethoxazole converted antibody-coated bacteria

1985 JAMA

88. Double-blind study to compare the selection of antibiotic resistance by amoxycillin or cephradine in the commensal flora. (Abstract)

Double-blind study to compare the selection of antibiotic resistance by amoxycillin or cephradine in the commensal flora. Elderly patients with acute urinary infections were treated in a double-blind study with either amoxycillin or cephradine. In 52 patients who had received amoxycillin for one week about a third of all intestinal Escherichia coli were highly resistant to amoxycillin, and many were resistant to tetracycline, trimethoprim, or chloramphenicol. Cephradine selected less resistance (...) . At a week after completion of chemotherapy, cephradine-resistant E coli were replaced by sensitive cultures at a greater frequency than were amoxycillin-resistant E coli. Neither antibiotic altered the skin flora. Amoxycillin, but not cephradine, selected for Enterobacteriaceae in the saliva. The propensity of amoxycillin to select resistance in E coli will limit its usefulness in treating urinary infections.

1983 Lancet Controlled trial quality: uncertain

89. Treatment of chancroid by clavulanic acid with amoxycillin in patients with beta-lactamase-positive Haemophilus ducreyi infection. (Abstract)

Treatment of chancroid by clavulanic acid with amoxycillin in patients with beta-lactamase-positive Haemophilus ducreyi infection. Multiresistant strains of Haemophilus ducreyi, the aetiological agent of chancroid, are prevalent in Nairobi, Kenya, where tetracyclines and sulphonamides are no longer very effective in the treatment of chancroid. The following regimens (given three times daily for seven days) were compared in a double-blind randomised trial--amoxycillin 500 mg, amoxycillin 500 mg (...) and clavulanic acid 125 mg, and amoxycillin 500 mg and clavulanic acid 250 mg. 68 of 100 ulcers were culture-positive for H. ducreyi. All strains of H. ducreyi produced beta-lactamase. At day 7 none of the amoxycillin-treated patients had responded clinically or bacteriologically, whereas all but 2 of 56 patients treated with an amoxycillin/clavulanic-acid regimen had responded clinically and H. ducreyi had been eradicated from their ulcers. The combination of amoxycillin-clavulanic acid appears to be very

1982 Lancet Controlled trial quality: uncertain

90. Single-dose amoxicillin therapy for urinary tract infection. Multicenter trial using antibody-coated bacteria localization technique. (Abstract)

Single-dose amoxicillin therapy for urinary tract infection. Multicenter trial using antibody-coated bacteria localization technique. Urine specimens from 134 women with acute, uncomplicated urinary tract infection at three medical centers were examined by the antibody-coated bacteria (ACB) assay. Patients with negative assays (suggesting bladder infection alone) were randomized to receive either a single 3-g oral dose of amoxicillin trihydrate or conventional ten-day courses of sulfa (...) -methoxazole-trimethoprim or oral ampicillin sodium. Comparable results were obtained with the three regimens for ACG-negative infection: 90% eradication of the original organism with single-dose amoxicillin, 100% with sulfamethoxazole-trimethoprim, and 96% with ampicillin. The overall incidence of ACB positivity was 32.1%, ranging from 8% to 63% at the three institutions. This difference seemed to be related to the ease of access to medical care: women with easy access having low rates of ACB positivity

1980 JAMA Controlled trial quality: uncertain

91. Efficacy of single-dose and conventional amoxicillin therapy in urinary-tract infection localized by the antibody-coated bacteria technic. (Abstract)

Efficacy of single-dose and conventional amoxicillin therapy in urinary-tract infection localized by the antibody-coated bacteria technic. Urine specimens from 61 women with symptoms of cystitis who are infected with amoxicillin-sensitive organisms were examined by the antibody-coated bacteria assay. Patients with negative assays were randomized to receive either a single 3-g oral dose of amoxicillin or 10 days of amoxicillin, 250 mg, given by mouth four times per day (conventional therapy (...) ). Patients with positive assays received conventional therapy. All 43 patients without antibody-coated bacteria in the urine, 22 given single-dose therapy and 21 treated conventionally, were cured of their infection. Of 18 patients with antibody-coated bacteria, nine relapsed within one week of completion of conventional therapy. The results of the antibody-coated bacteria assay appear to predict the therapeutic response: both single-dose and conventional amoxicillin therapy are completely successful

1978 NEJM Controlled trial quality: uncertain

92. Comparative trial of amoxycillin and chloramphenicol in treatment of typhoid fever in adults. (Abstract)

Comparative trial of amoxycillin and chloramphenicol in treatment of typhoid fever in adults. A randomised clinical trial in 124 adult patients with typhoid fever, proved by blood culture, showed that amoxycillin in a dosage of 1 g. six-hourly for fourteen days is an alternative to chloramphenicol, which has hitherto been regarded as the drug of choice.

1975 Lancet